About us

PolyTherics provides a range of proprietary and complementary technologies and services to enable the development of better biopharmaceuticals.

These technologies and services enable you to:

  • Produce more homogeneous and stable antibody drug conjugates (ADCs)
  • Predict the immunogenicity of antibodies and biologics before they enter the clinic
  • Develop antibodies and proteins with reduced immunogenic potential
  • Develop manufacturing cell lines suitable for transfer to a cGMP facility
  • Optimise the pharmacokinetics and pharmacodynamics of biologics through site-specific conjugation of polymers, including novel low viscosity polymers
  • Produce novel bispecific product formats, and
  • Achieve targeted delivery through carbohydrate and protein interactions.

We offer product-specific technology licences for our conjugation, polymer and de-immunisation technologies following feasibility studies, and collaborative programmes. We welcome enquiries from organisations interested in applying our technologies to develop better biopharmaceuticals. Click here to find out how you can access PolyTherics’ technologies